APOLLO HOSPITALS ENTERPRISE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,171 INR | -0.04% |
|
-0.56% | +8.23% |
| 06-17 | Fortis, Apollo, Medanta, and Max Lead the Charge in Bidding War for Jaypee Healthcare | CI |
| 05-31 | Transcript : Apollo Hospitals Enterprise Limited, Q4 2024 Earnings Call, May 31, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 57% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 94.24 and 59.51 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.8 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +8.23% | 10.61B | - | ||
| -31.73% | 13.83B | B+ | ||
| -7.21% | 11.13B | B | ||
| +27.19% | 8.54B | B | ||
| -7.76% | 7.36B | A- | ||
| +7.87% | 6.83B | B- | ||
| +9.84% | 6.48B | D | ||
| +16.57% | 4.41B | B+ | ||
| -4.42% | 4.28B | - | ||
| +38.53% | 4.27B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- APOLLOHOSP Stock
- APOLLOHOSP Stock
- Ratings Apollo Hospitals Enterprise Limited
